Oppenheimer commented on Celgene (NASDAQ: CELG) following positive Revlimid/pomalidomide updates from ASCO:

The firm comments, "There remains significant interest ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE